anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Topical compsn. for preventing premature ejaculation comprising dibucaine, at least one chlorofluorohydrocarbon and a biologically acceptable diluent. When applied to the penis 1/2 to 2 hr. before intercourse it can interrupt the stimulus-response sequence during intercourse and extend the time before orgasm from a few seconds to 2 min., or from 1/2 - 5 min. to 15 - 20 min. It reduces the irritation and excessive stimulation of the penis by its local anaesthetic action. A prefd. concn. of dibucaine is 0.9 - 1.1% dissolved in a solvent such as ethanol or IPA and contg. an additive such as isopropyl myristate to retain the compsn. on the skin.
BACKGROUND: Pulmonary embolisms (PEs) exhibit clinical features similar to those of acute coronary syndrome (ACS), including electrocardiographic abnormalities and elevated troponin levels, which frequently lead to misdiagnoses in emergency situations.
CASE PRESENTATION: Here, we report a case of PE coinciding with chronic coronary syndrome in which the patient's condition was obscured by symptoms mimicking ACS. A 68-year-old female with syncope presented to the hospital. Upon admission, she was found to have elevated troponin levels and an electrocardiogram showing ST-segment changes across multiple leads, which initially led to a diagnosis of ACS. Emergency coronary arteriography revealed occlusion of the posterior branches of the left ventricle of the right coronary artery, but based on the complexity of the intervention, the occlusion was considered chronic rather than acute. On the 3rd day after admission, the patient experienced recurrent chest tightness and shortness of breath, which was confirmed as acute PE by emergency computed tomography pulmonary angiography. Following standardized anticoagulation treatment, the patient improved and was subsequently discharged.
CONCLUSIONS: This case report highlights the importance of recognizing the nonspecific features of PE. Clinicians should be vigilant when identifying other clinical features that are difficult to explain accompanying the expected disease, and it is necessary to carefully identify the causes to prevent missed diagnoses or misdiagnoses.
BACKGROUND: Although current guidelines(ESPEN guideline: Clinical nutrition in surgery and other guidelines) recommend preoperative immunonutrition for cachectic gastric cancer patients, the strength of the recommendation is weak, and the level of evidence is low. The benefits of preoperative immunonutrition still remain controversial.
PATIENTS AND METHODS: 112 patients with gastric cancer cachexia were enrolled in the study and randomly assigned in a 1:1 ratio to receive either preoperative enteral immunonutrition support (IN, n = 56) or standard enteral nutrition support (SEN, n = 56). The primary endpoint was the incidence of infectious complications, and the secondary endpoints included the nutritional indicators, inflammatory markers, immune parameters, postoperative recovery and complications and gastrointestinal intolerance reactions.
RESULTS: The incidence of postoperative infectious complications(P = 0.040) and overall complications (P = 0.049)was significantly lower in the IN group compared to the SEN group. In terms of laboratory inflammatory indexes, patients in the IN group demonstrated significantly lower levels of white blood cells (WBC), C-reactive protein (CRP), and interleukin-6 (IL-6), as well as higher levels of lymphocytes (LYMPH) and immunoglobulin A (IgA), compared to patients in the SEN group, with statistically significant differences. In terms of clinical outcomes, the IN group had a shorter duration of antibiotic use (P = 0.048), shorter hospital stay (P = 0.018), and lower total hospital costs (P = 0.034) compared to the SEN group. The IN group also experienced significantly less weight loss after surgery (P = 0.043).
CONCLUSION: Preoperative administration of immunonutrition formula has a positive impact on the incidence of infectious complications in patients with gastric cancer cachexia after surgery. It improves patients' inflammatory and immune status, shortens hospital stays, and reduces healthcare costs. Preoperative use of immunonutrition may contribute to the improvement of prognosis in this high-risk population.
Depression is a serious illness that affects almost 19 million adults in the United States each year. Common symptoms of depression include persistent feelings of anxiety, guilt, or hopelessness; irregular sleep and appetite patterns; lethargy; disinterest in previously enjoyed activities; excessive irritability and restlessness; suicidal thoughts; and inability to concentrate. A person's depression can be attributed to a variety of causes, including biological and genetic factors, environmental influences, or developmental experiences. Among biological factors, a recently researched possible cause is the altered activity of specialized areas on brain nerve cells called serotonin receptors, which have been found to be at reduced levels in people with depression. The hormone serotonin is known to naturally influence mood, making depression treatments that aim to increase levels of serotonin important. Treatment for depression with cognitive behavioral therapy (CBT), which teaches ways to modify thoughts and behaviors that contribute to depression, may help in raising brain serotonin levels and in improving depressive symptoms. This study will examine changes in brain serotonin activity using single photon emission computed tomography (SPECT) imaging in people with depression before and after they receive CBT. The study will also use SPECT imaging to compare brain serotonin activity of non-depressed healthy participants with that of depressed participants.

Participation in this study will last between 12 and 14 weeks. All participants will first undergo an initial evaluation that will include questions about medical history, a physical exam, a blood draw, a urine test, and an electrocardiogram (ECG). Participants will then undergo an ADAM (a selective radioligand for SPECT imaging) SPECT scan. During the ADAM SPECT scan visit, participants will undergo an injection of the ADAM, an ECG, blood pressure monitoring, and a 60-minute SPECT scan. If necessary, participants may also be asked to have a magnetic resonance imaging (MRI) brain scan after completing the SPECT scan.

Depressed participants will then attend at least once weekly CBT sessions for 12 weeks. During the 45-minute sessions, participants will meet with a therapist to learn ways to adjust thoughts and behaviors that may be adding to their depression. After completing the 12 weeks of CBT, all participants will be re-evaluated by a study doctor and, if still in good health, will undergo a repeat ADAM SPECT scan.
PURPOSE:To prevent the lowering of plasminogen activity in the heat-treatment for the inactivation of contaminative viruses, by heating a plasminogen- containing aqueous solution in the presence of saccharose and aprotinin. CONSTITUTION:A plasminogen-containing aqueous solution originated from human plasma and human placenta is heated in the presence of saccharose and aprotinin to inactivate contaminative viruses (e.g. hepatitis virus). Similar to various other blood preparations, it is necessary to carry out the heat- treatment of a plaminogen preparation e.g. at 60 deg.C for 10hr to inactivate contam inative viruses, however, major part of plasminogen is also inactivated by con ventional heat-treatment. The inactivation of plasminogen in heat-treatment can be prevented by adding sucrose to the plasminogen-containing aqueous solution at a final concentration of 0.5g/ml - saturated concentration and aprotinin at a final concentration of >=1.5 KIU/ml.
Subjects are invited to participate in this study that have undergone a procedure as their standard of care. This procedure is known as Selective Internal Radiation Therapy (SIRT), a procedure designed for the treatment of cancer in the liver. This includes cancer that has started in the liver as well as cancer that has spread to the liver. The purpose of the study is to collect blood samples to assess for "biological markers," or substances within the blood that may promote cancer growth by causing new blood vessels to form. This study will also use a new method of analyzing medical imaging (CT scan, PET scan) to try and better understand how cancer in the liver forms new blood vessels. SIRT is standard therapy and not part of this study. This study involves blood draws only.
Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
Patients will start therapy with Hydroxyethyl starch instead of normal saline (6% hetastarch 600/0.75 in 0.9% sodium chloride) with a dose of 500 cc in 6 hours. Additionally, patient will receive the standard ALP treatment according to TUPTC protocol in the same order of placebo.
This application addresses "Studies to improve access and utilization of HIV counseling and testing" for "HIV/AIDS and AIDS-related co-infections" such as "hepatitis C virus (HCV), other sexually transmitted infections (STIs)" that are part of PA-07-307 Drug Abuse Aspects of HIV/AIDS. The only rapid tests that are approved for use in the US currently are for HIV infection. Tests for other conditions such as hepatitis C (HCV) and syphilis are in use in other countries. In response to an Opportunity that the CDC published in the Federal Register, there are now candidate rapid test kits for HCV and syphilis available for experimental use in the US. Different combinations of rapid and standard tests will be offered to participants in a four-arm trial to assess which tests are accepted by the participants. Only a minority of clients at CBRS who have been offered the rapid test for HIV have accepted it. Those who chose rapid HIV tests were more likely to be male, educated, gay, young and White. They were less likely to be Black, or injection drug users. The proposed study has the potential to have a significant impact upon screening for HIV, syphilis, and HCV. Rapid tests have the potential to increase the receipt of test results, particularly among groups that are less likely to return for their results using traditional testing. The candidate tests are designed for Point of Care (either oral fluid and/or whole blood), and thus will require real-time testing, so the trial will be able to evaluate both the accuracy of the tests in settings of intended use and their acceptability to potential clients in real-world situations.
Water soluble irradiation targets are disclosed for the production of  186  Re and  188  Re. The irradiation targets are selected for both water solubility and absence of elements which would produce contaminating isotopes for medical therapeutic and diagnostic use. In one embodiment,  186  Re or  188  Re is produced by the direct irradiation of a water soluble irradiation target comprising  185  Re or  187  Re, respectively. Preferred targets for this purpose include aluminum perrhenate, lithium perrhenate and magnesium perrhenate. In another embodiment, a zirconyl tungstate generator comprising  188  W for the production of  186  Re is obtained by irradiating a soluble irradiation target comprising  186  W, dissolving the irradiated target in aqueous solution, reacting the dissolved target with an aqueous solution comprising zirconyl ion to form an insoluble zirconium tungstate precipitate and disposing the precipitate in an elutable container. Preferred irradiation targets for this purpose include sodium tungstate and lithium tungstate. In each of the foregoing embodiments, the irradiation target is readily soluble in aqueous solution and may be used directly in solution form after irradiation, such as for ligand conjunction for medical diagnostic or therapeutic purposes, without cumbersome dissolution, neutralization, purification and other processing steps involving irradiated materials inherent in prior  186  Re and  188  Re production methods.
The control group included low-risk pregnant women who did not have polyhydramnios. Women who had chromosomal or anatomical abnormalities, multiple pregnancies, oligohydramnios (AFI 5 cm), severe polyhydramnios, fetal growth restriction, elective cesarean section (CS), pre-existing conditions (hypertension, diabetes, thrombophilia), or obstetric complications (gestational hypertension, preeclampsia, gestational diabetes) were excluded.
A process for preparing a free-flowing microcapsules comprises (a) dispersing core particles in cyclohexane soln. contg. a hydrocarbon compd. and an ethylcellulose, (b) cooling the dispersion until the ethylcellulose seperates out from the dispersion to form coating walls around the core particles and (c) recovering the microcapsules.  The hydrocarbon compd. has a cyclohexane solubility, a mol. wt. of 150-3000 and a solubility parameter ( ) of 7-10 (cal/cm3)1/2 at 25≰C.  The microcapsules are used as pharmaceutically active compds. for a micro-encapsulation.
Males with the X-linked ymphoproliferative disease (XLPD) have a marked susceptibility to Epstein-Barr virus (EBV) disease. These boys develop very severe disease associated with infectious mononucleosis; others develop hypogammaglobulinemia or B cell lymphomas. Recent studies have linked the disease to a region of the X-chromosome. The purpose of this study is to determine the function of the gene responsible for XLPD. Blood samples or discarded tissues (e.g. previous biopsy or autopsy material) from patients with XLPD and their relatives will be analyzed to determine the precise genetic defect associated with the disease. Blood samples or discarded tissues from other patients with EBV-associated lymphoproliferative diseases and blood samples from normal individuals will be obtained to serve as controls. Knowledge gained from this study should provide important insights into the immunologic control of EBV lymphoproliferative disease associated with congenital or acquired immunodeficiency. In addition, identification of the molecular mechanisms for these diseases may provide clues to other EBV-associated diseases including nasopharyngeal carcinoma, Burkitt lymphoma, and Hodgkin's disease.
Obesity requires treatment to mitigate the potential development of further metabolic disorders, including diabetes, hyperlipidemia, tumor growth, and non-alcoholic fatty liver disease. We investigated the anti-obesity effect of a 30% ethanol extract of Eisenia bicyclis (Kjellman) Setchell (EEB) on 3T3-L1 preadipocytes and high-fat diet (HFD)-induced obese C57BL/6 mice. Adipogenesis transcription factors including peroxisome proliferator-activated receptor (PPAR)γ, CCAAT/enhancer-binding protein-alpha (C/EBPα), and sterol regulatory element-binding protein-1 (SREBP-1) were ameliorated through the AMP-activated protein kinase (AMPK) pathway by EEB treatment in differentiated 3T3-L1 cells. EEB attenuated mitotic clonal expansion by upregulating cyclin-dependent kinase inhibitors (CDKIs) while downregulating cyclins and CDKs. In HFD-fed mice, EEB significantly decreased the total body weight, fat tissue weight, and fat in the tissue. The protein expression of PPARγ, C/EBPα, and SREBP-1 was increased in the subcutaneous fat and liver tissues, while EEB decreased the expression levels of these transcription factors. EEB also inhibited lipogenesis by downregulating acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) expression in the subcutaneous fat and liver tissues. Moreover, the phosphorylation of AMPK and ACC was downregulated in the HFD-induced mouse group, whereas the administration of EEB improved AMPK and ACC phosphorylation; thus, EEB treatment may be related to the AMPK pathway. Histological analysis showed that EEB reduced the adipocyte size and fat accumulation in subcutaneous fat and liver tissues, respectively. EEB promotes thermogenesis in brown adipose tissue and improves insulin and leptin levels and blood lipid profiles. Our results suggest that EEB could be used as a potential agent to prevent obesity.
Toluene diisocyanate (TDI) is a major industrial compound that induces occupational asthma with steroid-resistant properties. Recent studies suggest that the gastrointestinal tract may be an effective target for the treatment of respiratory diseases. However, the alterations of the gut-lung axis in TDI-induced asthma remain unexplored. Therefore, in this study, a model of stable occupational asthma caused by TDI exposure was established to detect the alteration of the gut-lung axis. Exposure to TDI resulted in dysbiosis of the gut microbiome, with significant decreases in Barnesiella_intestinihominis, Faecalicoccus_pleomorphus, Lactobacillus_apodemi, and Lactobacillus_intestinalis, but increases in Alistipes_shahii and Odoribacter_laneus. The largest change in abundance was in Barnesiella_intestinihominis, which decreased from 12.14 per cent to 6.18 per cent. The histopathological abnormalities, including shorter length of intestinal villi, thinner thickness of muscularis, reduced number of goblet cells and inflammatory cell infiltration, were found in TDI-treated mice compared to control mice. In addition, increased permeability (evidenced by significantly reduced levels of ZO-1, Occludin and Claudin-1) and activation of TLR4/NF-κB signaling were observed in the intestine of these TDI-exposed mice. Concurrently, exposure to TDI resulted in airway hyperresponsiveness, overt cytokine production (e.g., IL-4, IL-5, IL-13, IL-25, and IL-33), and elevated IgE level within the respiratory tract. The expression of tight junction proteins is reduced and TLR4/NF-κB signaling is activated in the lung following TDI treatment. In addition, correlation analyses showed that changes in the gut microbiota were correlated with TDI exposure-induced airway inflammation. In conclusion, the present study suggests that the immune gut-lung axis may be involved in the development of TDI-induced asthma, which may have implications for potential interventions against steroid-resistant asthma.
Patients who will undergo cardiac surgery between 01 September 2020 and 01 April 2021 and meet the inclusion criteria will be able to participate in the study with their verbal and written consents. The assignment of the patients to the control or experimental group will be done with the random numbers table created using the generate number function in the Excel program. This study will be conducted in 64 patients (32 patients in each group) who will be operated in cardiac surgery at Istanbul Yeni Yüzyıl University GOP hospital. In order to determine the postoperative anxiety and pain management effects of the patient visit of the operating room nurse, the pre-test-post-test control group design will be made quasi-experimental in non-randomized groups. The variables of the study were anxiety, pain, and analgesic use. As data collection tools, 'Sampling Criteria Form' will be used for sampling and 'State Trait Anxiety Scale I-II ' will be used for anxiety assessment. "VAS (Visual Analogue Scale)" will be used for pain assessment, and "Analgesic Follow-up Form" developed by the researcher will be used for the recording of analgesics. The "Data Recording Form" created by the researcher will be used to record the demographic and medical data of the patients.

The researcher will apply the "State-Trait Anxiety Scale" to determine the level of anxiety after visiting the patient's room and obtaining verbal and written permission from the patient. If the patient is in the control group, it will be ensured that the institutional procedures are implemented and followed without any intervention (without visiting and verbal training printed booklet). In the experimental group,the operating room nurse, who is given intervention training , will be provided to visit the patient before surgery. After the verbal training of the operating room nurse, a printed booklet will be left for the patient to read. It will be ensured that the nurse visiting the patient in her room will be welcomed in the operating room. After the operation, the pain level of the patient will be monitored by the Visual Assessment Scale (VAS) in the intensive care and inpatient floor. Pain level and use of analgesics will be monitored at the first 72 hours and thereafter until the thoracic tubes are removed. The analgesics ordered for the patient will be recorded according to time, name, dose and route of administration. For these records, "Analgesic Registration Form" developed by the researcher will be used.Patients with prolonged intensive care stay (over 96 hours) and returning to intensive care will be excluded from the evaluation. If these patients are excluded from the study, an "intention to treat" (ITT) analysis will be performed to assess the realistic effect of the intervention. "State-Trait Anxiety Scale" will be applied again by the researcher on the 24th hour to determine the postoperative anxiety level of all patients.
The invention provides Tongjingbaoyuangao which is made of natural traditional Chinese medicine such as Radix Astragali, safflower, motherwort, donkey-hide gelatin and the like with high technology. The invention relates to juice for treating gynecological diseases such as stubborn gynecological diseases, infertility and the like, and is a novel product with high technology. The juice is packed in a bottle. When using, the juice is mixed in boiled water for oral taking. Use of the juice is convenient, and treatment effect is unique. The juice is suitable for long-term taking. The juice has the efficacies of invigorating blood circulation, enriching blood, smoothing qi activity, stimulating menstrual flow, and relieving pain. The juice also has an efficacy of antibiosis and antiphlogosis. The juice is suitable for treating female abnormal menstruation, amenorrhoea, dysmenorrhoea, blood-insufficiency, lack of menstruation, yellow complexion, blood stasis, stomachache and various stubborn gynaecology diseases (pelvic inflammation, adnexitis, endometritis), and has unique curative effect for infertility caused by abnormal menstruation.
Disclosed is a novel anti-cancer agent which is less likely to be excreted from a cancer cell and is suitable for the local treatment against a cancer cell. The anti-cancer agent comprises a rotaxane compound represented by the chemical formula (I) as an active ingredient. The rotaxane compound is composed of two moieties; namely, a rod-like moiety having a relatively large molecule attached to each of both ends, and a cyclic moiety (a crown ether) into which the rod-like moiety is inserted. The cyclic moiety cannot be detached from the rod-like moiety, because the rod-like moiety has a relatively large molecule attached to each of both ends and the relatively large molecule serves as a stopper for the detachment. The bond between the two moieties is not a covalent bond. Therefore, the shape of the molecule can be varied readily, and the uptake of the molecule via a receptor becomes relatively difficult. However, once the molecule is introduced into a cancer cell, the proliferation of the cancer cell can be inhibited.
Disclosed is a medicine that is efficacious in treating and preventing cancer, etc. and shows little side effects. An antitumor agent according to the present invention comprises at least one kind of leukotriene inhibitor as an active ingredient. The leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists. As preferable examples thereof, montelukast, zafirlukast, pranlukast, zileuton, pharmaceutically acceptable salts of these compounds and pharmaceutically acceptable solvates of these compounds and the aforesaid salts may be cited. Also, the leukotriene inhibitor is usable as an agent for alleviating a pain accompanied by tumor and a stromal hyperplasia inhibitor.